{
  "ticker": "OCC",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968027",
  "id": "02968027",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250710",
  "time": "0903",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250710/pdf/06lnpc6jp9gcf7.pdf",
  "summary": "- **First US Sales Revenue**: Orthocell has recorded first sales revenue from its Remplir\u2122 nerve repair product in the US.  \n- **Key Milestone**: Follows first surgical use on 26 June 2025 and early cases via specialist distributors.  \n- **Market Potential**: Targets US nerve repair market estimated at **US$1.6 billion**; global addressable market exceeds **US$3.5 billion**.  \n- **Cash Position**: **A$28.6 million** cash at bank (as of 30 June 2025), no debt.  \n- **Commercial Progress**: Validated order fulfillment and logistics with partner Uniphar.  \n\n*No capital markets actions (e.g., raising, halt) or trading-sensitive dates identified.*",
  "usage": {
    "prompt_tokens": 1944,
    "completion_tokens": 158,
    "total_tokens": 2102,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-09T23:20:42.427464"
}